Hua Medicine (Shanghai) Ltd.
HUMDF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.10 | -0.15 | -0.19 |
| FCF Yield | -2.88% | -17.95% | -15.75% | 20.06% |
| EV / EBITDA | -37.50 | -1.48 | -2.03 | -9.36 |
| Quality | ||||
| ROIC | -4.91% | -12.65% | -13.53% | -13.48% |
| Gross Margin | 54.19% | 50.23% | 46.52% | -106.27% |
| Cash Conversion Ratio | -0.07 | 1.77 | 1.59 | -5.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 148.22% | 120.72% | 98.23% | 44.25% |
| Free Cash Flow Growth | 56.28% | 15.23% | -136.27% | 149.47% |
| Safety | ||||
| Net Debt / EBITDA | 12.96 | 5.27 | 5.71 | 6.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 0.60 | 0.58 | 0.19 |
| Cash Conversion Cycle | 104.91 | 97.18 | 56.48 | 126.82 |